Somerville Kurt F maintained its position in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,661 shares of the medical research company’s stock at the close of the 2nd quarter. Somerville Kurt F’s holdings in Amgen were worth $458,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. TrimTabs Asset Management LLC grew its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. American Beacon Advisors Inc. acquired a new stake in shares of Amgen in the first quarter valued at about $106,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at about $121,000. Institutional investors and hedge funds own 78.14% of the company’s stock.
AMGN has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research note on Friday, June 30th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $180.00 price objective on shares of Amgen in a research note on Monday, May 22nd. Credit Suisse Group set a $177.00 price objective on Amgen and gave the company a “hold” rating in a research note on Friday, July 14th. Finally, Morgan Stanley raised their price objective on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and an average price target of $186.04.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/2887035/amgen-inc-amgn-position-maintained-by-somerville-kurt-f.html.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.90% during mid-day trading on Tuesday, hitting $188.17. The company had a trading volume of 1,648,583 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $188.85. The firm has a market cap of $137.30 billion, a PE ratio of 17.14 and a beta of 1.35. The firm’s 50 day moving average is $173.58 and its 200-day moving average is $168.69.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the company posted $2.84 EPS. The company’s revenue was up 2.1% compared to the same quarter last year. On average, equities analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.47%. Amgen’s dividend payout ratio is currently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.